• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

代谢功能障碍相关脂肪性肝病患者的自我管理:影响因素及其对再入院的影响。

Self-management in patients with metabolic dysfunction-associated steatotic liver disease: influencing factors and impact on readmission.

机构信息

Department of Infectious Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, China.

Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, No.2 Fuxue Lane, Lucheng District, Wenzhou City, Zhejiang Province, 325000, China.

出版信息

J Health Popul Nutr. 2024 Aug 31;43(1):134. doi: 10.1186/s41043-024-00618-z.

DOI:10.1186/s41043-024-00618-z
PMID:39217400
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11366125/
Abstract

BACKGROUND

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common chronic liver disease.

OBJECTIVE

This study aimed to investigate the self-management ability of patients with MASLD, analyse related factors that may affect self-management ability and evaluate the impact of this ability on readmission.

METHODS

The study recruited patients with MASLD admitted to the Department of Infectious Diseases, First Affiliated Hospital of Wenzhou Medical University, between February and October 2021 using the random sampling method. The MASLD diagnosis was based on the guidelines for the prevention and treatment of MASLD. An analysis of patients' self-management ability was conducted using the self-management ability scale for patients with MASLD. Multiple linear regression analysis was used to analyse the factors influencing this self-management ability, and the readmission rate within 1 year was tracked. The patients were rediagnosed as having MASLD upon readmission to the hospital.

RESULTS

A total of 241 baseline data items and self-management scale scores for patients with MASLD were collected and investigated. In our study, the normal score range for the self-management scale was 31-155 points, and the self-management scale scores for patients with MASLD was 91.24 ± 16.98, with a low level of self-management accounting for 52.7% and a medium level accounting for 44.8%. The results of the multiple linear regression analysis revealed that marital status, smoking history, fatty liver severity and education were the main factors affecting self-management ability (P < 0.05). The readmission rates were 18.25%, 7.48% and 0%, respectively, after 1 year of follow-up; the difference in survival distribution was statistically significant (P < 0.05).

CONCLUSION

The self-management ability of patients with MASLD is relatively low and is primarily influenced by factors such as marital status, smoking history, the severity of fatty liver disease and level of education, which also affect the readmission rate of patients within 1 year.

摘要

背景

代谢相关脂肪性肝病(MASLD)是一种常见的慢性肝病。

目的

本研究旨在探讨 MASLD 患者的自我管理能力,分析可能影响自我管理能力的相关因素,并评估该能力对再入院的影响。

方法

本研究采用随机抽样法,于 2021 年 2 月至 10 月招募了温州医科大学第一附属医院感染科收治的 MASLD 患者。MASLD 诊断基于 MASLD 的防治指南。采用 MASLD 患者自我管理能力量表分析患者的自我管理能力。采用多元线性回归分析影响自我管理能力的因素,并跟踪患者在 1 年内的再入院率。患者在再次入院时被重新诊断为 MASLD。

结果

共收集并调查了 241 例 MASLD 患者的基线数据和自我管理量表评分。本研究中,自我管理量表的正常评分范围为 31-155 分,MASLD 患者的自我管理量表评分为 91.24±16.98 分,自我管理能力低的占 52.7%,中等水平的占 44.8%。多元线性回归分析结果表明,婚姻状况、吸烟史、脂肪肝严重程度和教育程度是影响自我管理能力的主要因素(P<0.05)。随访 1 年后,再入院率分别为 18.25%、7.48%和 0%,生存分布差异有统计学意义(P<0.05)。

结论

MASLD 患者的自我管理能力相对较低,主要受婚姻状况、吸烟史、脂肪肝严重程度和教育程度等因素的影响,这些因素也影响患者在 1 年内的再入院率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd3/11366125/7ea311c45ceb/41043_2024_618_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd3/11366125/7ea311c45ceb/41043_2024_618_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd3/11366125/7ea311c45ceb/41043_2024_618_Fig1_HTML.jpg

相似文献

1
Self-management in patients with metabolic dysfunction-associated steatotic liver disease: influencing factors and impact on readmission.代谢功能障碍相关脂肪性肝病患者的自我管理:影响因素及其对再入院的影响。
J Health Popul Nutr. 2024 Aug 31;43(1):134. doi: 10.1186/s41043-024-00618-z.
2
The serum uric acid to apolipoprotein A1 ratio is independently correlated with metabolic dysfunction-associated steatotic liver disease in type 2 diabetes mellitus: findings from a single national metabolic management center cohort.血清尿酸与载脂蛋白A1比值与2型糖尿病中代谢功能障碍相关脂肪性肝病独立相关:来自单一国家代谢管理中心队列的研究结果
Front Endocrinol (Lausanne). 2025 Jun 4;16:1619003. doi: 10.3389/fendo.2025.1619003. eCollection 2025.
3
Modeling the health and economic impact of pharmacologic therapies for MASLD in the United States.模拟美国药物治疗非酒精性脂肪性肝炎相关肝病的健康和经济影响。
J Hepatol. 2025 Jan 18. doi: 10.1016/j.jhep.2025.01.009.
4
Association of uric acid levels with the development of metabolic dysfunction-associated and metabolic and alcohol-related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.尿酸水平与代谢功能障碍相关及代谢和酒精相关/伴发的脂肪性肝病发生的关联:一项针对接受健康检查的日本参与者的研究
Endocr J. 2025 Jun 2;72(6):671-687. doi: 10.1507/endocrj.EJ24-0622. Epub 2025 Feb 26.
5
All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease.慢性乙型肝炎合并脂肪性肝病患者的全因死亡率和特定病因死亡率。
J Hepatol. 2024 Dec 14. doi: 10.1016/j.jhep.2024.12.009.
6
Epidemiological trends and burden of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa region: a 32-year analysis of health impact.中东和北非地区代谢功能障碍相关脂肪性肝病的流行病学趋势与负担:一项为期32年的健康影响分析
J Health Popul Nutr. 2025 Jun 18;44(1):207. doi: 10.1186/s41043-025-00973-5.
7
Aural toilet (ear cleaning) for chronic suppurative otitis media.慢性化脓性中耳炎的耳道清理(耳部清洁)
Cochrane Database Syst Rev. 2025 Jun 9;6(6):CD013057. doi: 10.1002/14651858.CD013057.pub3.
8
Prognostic factors for return to work in breast cancer survivors.乳腺癌幸存者恢复工作的预后因素。
Cochrane Database Syst Rev. 2025 May 7;5(5):CD015124. doi: 10.1002/14651858.CD015124.pub2.
9
Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis.女性高密度脂蛋白胆固醇水平低和男性高甘油三酯血症:无脂肪变性个体中代谢相关脂肪性肝病发病的预测因素。
J Gastroenterol. 2025 Mar 18. doi: 10.1007/s00535-025-02242-y.
10
Interventions for fertility preservation in women with cancer undergoing chemotherapy.对接受化疗的癌症女性进行生育力保存的干预措施。
Cochrane Database Syst Rev. 2025 Jun 19;6:CD012891. doi: 10.1002/14651858.CD012891.pub2.

引用本文的文献

1
The Impact of Social Determinants of Health on Metabolic Dysfunction-Associated Steatotic Liver Disease Among Adults in the United States.社会健康决定因素对美国成年人代谢功能障碍相关脂肪性肝病的影响
J Clin Med. 2025 Aug 4;14(15):5484. doi: 10.3390/jcm14155484.
2
Correction: Self-management in patients with metabolic dysfunction-associated steatotic liver disease: influencing factors and impact on readmission.更正:代谢功能障碍相关脂肪性肝病患者的自我管理:影响因素及对再入院的影响
J Health Popul Nutr. 2025 Jun 18;44(1):204. doi: 10.1186/s41043-025-00936-w.
3
Correlation between family function and self-management abilities in patients with metabolic dysfunction-associated steatotic liver disease.

本文引用的文献

1
Almost identical values of various non-invasive indexes for hepatic fibrosis and steatosis between NAFLD and MASLD in Asia.在亚洲,非酒精性脂肪性肝病(NAFLD)和代谢相关脂肪性肝病(MASLD)之间,用于评估肝纤维化和脂肪变性的各种非侵入性指标的值几乎相同。
J Hepatol. 2024 Apr;80(4):e155-e157. doi: 10.1016/j.jhep.2023.12.030. Epub 2024 Jan 13.
2
Advancements in metabolic-associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions.代谢相关脂肪性肝病研究进展:诊断、小分子药物研发及未来方向。
Hepatol Res. 2024 Mar;54(3):222-234. doi: 10.1111/hepr.14008. Epub 2024 Jan 22.
3
Reclassification of nonalcoholic fatty liver disease: a multi-society Delphi consensus statement.
代谢功能障碍相关脂肪性肝病患者家庭功能与自我管理能力的相关性
J Health Popul Nutr. 2025 Jan 8;44(1):6. doi: 10.1186/s41043-024-00714-0.
非酒精性脂肪性肝病的重新分类:多学会德尔菲共识声明
Clin Exp Dermatol. 2023 Nov 16;48(12):1418-1421. doi: 10.1093/ced/llad283.
4
Clinical study on the evaluation of liver fibrosis by ultrasound elastography combined with platelet count model.超声弹性成像联合血小板计数模型对肝纤维化的临床研究。
Clin Hemorheol Microcirc. 2023;84(2):205-214. doi: 10.3233/CH-231766.
5
Nonalcoholic fatty liver disease from a primary care perspective.从基层医疗角度看非酒精性脂肪性肝病。
Diabetes Obes Metab. 2023 Jun;25(6):1421-1433. doi: 10.1111/dom.15016. Epub 2023 Mar 24.
6
Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment.非酒精性脂肪性肝病(NAFLD)发病机制及天然产物的防治。
Int J Mol Sci. 2022 Dec 7;23(24):15489. doi: 10.3390/ijms232415489.
7
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).美国临床内分泌学会临床实践指南:原发性保健和内分泌学临床环境中非酒精性脂肪性肝病的诊断和管理:由美国肝病研究协会(AASLD)共同赞助。
Endocr Pract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.
8
Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review.日本非酒精性脂肪性肝病管理中生活方式改变的临床实践建议:专家综述。
J Gastroenterol. 2021 Dec;56(12):1045-1061. doi: 10.1007/s00535-021-01833-9. Epub 2021 Oct 31.
9
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者风险分层与管理的临床护理路径。
Gastroenterology. 2021 Nov;161(5):1657-1669. doi: 10.1053/j.gastro.2021.07.049. Epub 2021 Sep 20.
10
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.2020 年非酒精性脂肪性肝病/非酒精性脂肪性肝炎临床实践循证指南。
J Gastroenterol. 2021 Nov;56(11):951-963. doi: 10.1007/s00535-021-01796-x. Epub 2021 Sep 17.